Madrigal Pharmaceuticals price target raised to $239 from $154 at BofA
BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...
Madrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 1-Year High on Better-Than-Expected Earnings
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) reached a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as ...
Decoding Madrigal Pharmaceuticals's Options Activity: What's the Big Picture?
Benzinga's options scanner spotted 9 options trades for Madrigal Pharmaceuticals. This is not a typical pattern. The sentiment among these major traders is split, with 44% bullish and 44% bearish.
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Evercore ISI Remains a Buy on Kiniksa Pharmaceuticals (KNSA)
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA – Research Report) yesterday and set a price target ...